← Eichor
Condition: Atezolizumab Bevacizumab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Atezolizumab Bevacizumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be
Phase 2 · 3 location(s) · Asan Medical Center · NCT07010497The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage Hepato
Phase 3 · 72 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT04803994The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Phase 2 · 2 location(s) · Inova Health Care Services · NCT06789757Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
Phase 2 · 1 location(s) · Japan Breast Cancer Research Group · NCT06793553Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a
Phase 2 · 7 location(s) · Centre Hospitalier Universitaire Vaudois · NCT07263438Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Phase 2 · 13 location(s) · National Cancer Institute (NCI) · NCT04981509Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Phase 4 · 1 location(s) · The Methodist Hospital Research Institute · NCT05185505Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Phase 4 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT07059494Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
NA · 1 location(s) · Tanta University · NCT06961526Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07192185Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
NA · 1 location(s) · Yonsei University · NCT06595108Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT06339424Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06323382Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metast
Phase 2 · 16 location(s) · Academic and Community Cancer Research United · NCT05168163SBRT With Atezo/Bev for HCC
Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT05488522Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab P
Phase 2 · 14 location(s) · National Cancer Centre, Singapore · NCT05377034Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT07091942Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC
Phase 2 · 1 location(s) · Asan Medical Center · NCT06819566Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT06605664The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
Phase 2/Phase 3 · 1 location(s) · Eastern Hepatobiliary Surgery Hospital · NCT07285850Ate-Bev Early Response Prediction Model in Advanced HCC
Phase N/A · 1 location(s) · Seoul National University Hospital · NCT05763277A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezol
Phase 1/Phase 2 · 9 location(s) · Rznomics, Inc. · NCT06695026dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT06609863Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab i
Phase 2 · 6 location(s) · National Cancer Centre, Singapore · NCT05516628SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
Phase 2 · 2 location(s) · Chinese University of Hong Kong · NCT06823375NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy
Phase N/A · 1 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT07365930A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectab
Phase 1/Phase 2 · 21 location(s) · Tvardi Therapeutics, Incorporated · NCT05440708Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarc
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06439485TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
NA · 1 location(s) · Third Affiliated Hospital, Sun Yat-Sen University · NCT05984511
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.